Glucose/Insulin Clamp on Solid Organ Transplant (Liver, Kidney, Pancreas and Heart) on Cadaveric Donors

Complication of Transplanted Organ, Nos Clinical Trial

Official title: Glucose/Insulin Clamp on Solid Organ Transplant (Liver, Kidney, Pancreas and Heart) on Cadaveric Donors

Status Recruiting

Clinical Trial Summary

Our objective in this study will be to determine if implementing the glucose/insulin clamp (GICT) on cadaveric organ donors can:

• Prevent hyperglycaemia

• Drop in the inflammatory cytokine response after brain death after a minimum of 6 hours therapy with the GICT prior to organ procurement.

• Assess organ (heart, liver, pancreas and kidney) survival at one year post-transplant

• Assess graft function by evaluating:

• Liver: post-transplant liver function score (PTLF)

• Kidney: graft function as defined by UNOS (immediate graft function IGF, slow graft function SGF and delayed graft function DGF and

• Pancreas: 7 day post-transplant insulin requirement, C-peptide and C-RP levels at day one and seven post-transplantation

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label

Related Conditions & MeSH terms

• Complication of Transplanted Organ, Nos

• NCT number: NCT01304290
• Study type: Interventional
• Source: McGill University Health Center
• Contact: Ayat Salman, MSc
• Phone: 5149341934
• Email: ayat.salman@muhc.mcgill.ca
• Status: Recruiting
• Phase: N/A
• Start date: October 2010